NR 601 Week 5 Quiz: Thyroid Management & Diabetes Care |
Questions And Answers (Verified Answers) - Chamberlain
University - 90 Questions and Answers Already Graded A+
Premium Exam Tested And Verified
Subject Area Endocrinology - Thyroid Management and Diabetes Care
Description This exam assesses advanced knowledge of thyroid disorders and diabetes
mellitus, including pathophysiology, pharmacotherapy, and evidence-based
management. Questions integrate clinical decision-making, interpretation of
diagnostic data, and application of current guidelines for conditions such as
hyperthyroidism, hypothyroidism, type 1 and type 2 diabetes, and diabetic
emergencies.
Expected Grade A+
Total Questions 90
Duration 3 hours
Learning Outcomes 1. Differentiate between types of thyroid dysfunction and select appropriate
treatment strategies.
2. Interpret thyroid function tests and adjust therapy based on patient response.
3. Apply current ADA/EASD guidelines for individualized diabetes management.
4. Identify and manage acute and chronic complications of diabetes.
5. Evaluate the impact of comorbid conditions on thyroid and diabetes care.
Accreditation Accredited by the Commission on Collegiate Nursing Education (CCNE) - aligns
with AACN Essentials and NONPF competencies.
Page 1
,1. In a patient with primary hypothyroidism, which of the following scenarios would
most likely require a dose reduction of levothyroxine?
A. Concomitant use of oral estrogen therapy
B. Initiation of a proton pump inhibitor
C. Weight loss of 10% body mass over 3 months
D. Addition of a beta-blocker for tachycardia
Answer: C. Weight loss of 10% body mass over 3 months
Levothyroxine dose is weight-based; significant weight loss reduces the volume of
distribution, leading to relative overdose. Estrogen increases TBG, requiring dose
increase. PPIs may reduce absorption, needing dose increase. Beta-blockers do not
directly affect thyroid hormone metabolism.
2. A patient with Graves' disease develops atrial fibrillation. Which of the following
management strategies is most appropriate?
A. Initiate amiodarone for rhythm control
B. Start metoprolol and methimazole
C. Perform cardioversion before achieving euthyroid state
D. Administer radioactive iodine as first-line therapy
Answer: B. Start metoprolol and methimazole
Beta-blockers control heart rate in thyrotoxic atrial fibrillation, and methimazole
reduces thyroid hormone production. Amiodarone contains iodine and can worsen
hyperthyroidism. Cardioversion is less effective if the patient is not euthyroid. RAI is
not immediate and does not address the acute arrhythmia.
3. Which of the following best explains the mechanism of action of metformin
beyond its effect on hepatic gluconeogenesis?
A. Increases insulin secretion from pancreatic beta cells
B. Inhibits alpha-glucosidase in the small intestine
C. Activates AMPK in skeletal muscle, enhancing glucose uptake
D. Blocks sodium-glucose cotransporter-2 in the renal tubules
Answer: C. Activates AMPK in skeletal muscle, enhancing glucose uptake
Metformin activates AMPK, which increases insulin sensitivity and glucose uptake in
muscle. It does not stimulate insulin secretion (sulfonylureas do), does not inhibit
alpha-glucosidase (acarbose), and does not block SGLT2 (empagliflozin).
Page 2
,4. In a patient with type 2 diabetes and established atherosclerotic cardiovascular
disease (ASCVD), which of the following antihyperglycemic agents is recommended
as first-line add-on to metformin according to current ADA guidelines?
A. Insulin glargine
B. SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit
C. DPP-4 inhibitor
D. Thiazolidinedione
Answer: B. SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit
ADA guidelines recommend an SGLT2 inhibitor or GLP-1 RA with cardiovascular
benefit (e.g., empagliflozin, liraglutide) as first add-on for patients with ASCVD. Insulin
is not first-line. DPP-4 inhibitors have neutral CV effects. Thiazolidinediones may
increase heart failure risk.
5. A patient with type 1 diabetes presents with nausea, vomiting, and abdominal
pain. Capillary blood glucose is 450 mg/dL. Urine ketones are large. Which of the
following laboratory findings is most consistent with diabetic ketoacidosis (DKA)
rather than hyperosmolar hyperglycemic state (HHS)?
A. Serum osmolality 320 mOsm/kg
B. Serum bicarbonate 12 mEq/L
C. Serum sodium 150 mEq/L
D. Blood urea nitrogen 30 mg/dL
Answer: B. Serum bicarbonate 12 mEq/L
Low serum bicarbonate indicates metabolic acidosis, a hallmark of DKA. HHS
typically has higher osmolality (>320), higher sodium due to dehydration, and elevated
BUN, but bicarbonate is usually >18 mEq/L.
Page 3
, 6. Which of the following statements best describes the role of thyroid peroxidase
antibodies (TPOAb) in the diagnosis of autoimmune thyroid disease?
A. TPOAb is elevated in Graves' disease but not in Hashimoto's thyroiditis
B. TPOAb positivity confirms the diagnosis of Hashimoto's thyroiditis regardless of thyroid
function
C. TPOAb is a marker of autoimmune thyroid disease but not specific to a single condition
D. TPOAb levels correlate directly with thyroid hormone levels in hyperthyroidism
Answer: C. TPOAb is a marker of autoimmune thyroid disease but not specific to a
single condition
TPOAb is present in both Hashimoto's thyroiditis and Graves' disease, indicating
autoimmune etiology. It does not confirm Hashimoto's alone (B is false). It is not
exclusive to Graves' (A). TPOAb levels do not correlate with thyroid hormone levels
(D).
7. A patient with subclinical hypothyroidism (TSH 6.5 mIU/L, free T4 normal) is
planning pregnancy. Which of the following is the most appropriate management?
A. No treatment; monitor TSH every 6 months
B. Start levothyroxine to achieve TSH <2.5 mIU/L
C. Start methimazole to prevent fetal goiter
D. Perform thyroid ultrasound and fine-needle aspiration
Answer: B. Start levothyroxine to achieve TSH <2.5 mIU/L
In pregnancy planning, subclinical hypothyroidism should be treated to reduce risk of
adverse outcomes. Target TSH <2.5 mIU/L. Methimazole is for hyperthyroidism.
Ultrasound/aspiration is not indicated unless nodules are present.
8. Which of the following is a key advantage of using continuous glucose monitoring
(CGM) over self-monitoring of blood glucose (SMBG) in the management of type 1
diabetes?
A. CGM eliminates the need for insulin dose adjustments
B. CGM provides real-time glucose trends and alerts for hypoglycemia
C. CGM is less expensive than SMBG
D. CGM measures glycated hemoglobin directly
Answer: B. CGM provides real-time glucose trends and alerts for hypoglycemia
CGM offers trend data and alarms for hypo/hyperglycemia, improving glycemic
control and reducing hypoglycemia. It does not replace insulin adjustments (A), is more
expensive (C), and does not measure HbA1c (D).
Page 4
Questions And Answers (Verified Answers) - Chamberlain
University - 90 Questions and Answers Already Graded A+
Premium Exam Tested And Verified
Subject Area Endocrinology - Thyroid Management and Diabetes Care
Description This exam assesses advanced knowledge of thyroid disorders and diabetes
mellitus, including pathophysiology, pharmacotherapy, and evidence-based
management. Questions integrate clinical decision-making, interpretation of
diagnostic data, and application of current guidelines for conditions such as
hyperthyroidism, hypothyroidism, type 1 and type 2 diabetes, and diabetic
emergencies.
Expected Grade A+
Total Questions 90
Duration 3 hours
Learning Outcomes 1. Differentiate between types of thyroid dysfunction and select appropriate
treatment strategies.
2. Interpret thyroid function tests and adjust therapy based on patient response.
3. Apply current ADA/EASD guidelines for individualized diabetes management.
4. Identify and manage acute and chronic complications of diabetes.
5. Evaluate the impact of comorbid conditions on thyroid and diabetes care.
Accreditation Accredited by the Commission on Collegiate Nursing Education (CCNE) - aligns
with AACN Essentials and NONPF competencies.
Page 1
,1. In a patient with primary hypothyroidism, which of the following scenarios would
most likely require a dose reduction of levothyroxine?
A. Concomitant use of oral estrogen therapy
B. Initiation of a proton pump inhibitor
C. Weight loss of 10% body mass over 3 months
D. Addition of a beta-blocker for tachycardia
Answer: C. Weight loss of 10% body mass over 3 months
Levothyroxine dose is weight-based; significant weight loss reduces the volume of
distribution, leading to relative overdose. Estrogen increases TBG, requiring dose
increase. PPIs may reduce absorption, needing dose increase. Beta-blockers do not
directly affect thyroid hormone metabolism.
2. A patient with Graves' disease develops atrial fibrillation. Which of the following
management strategies is most appropriate?
A. Initiate amiodarone for rhythm control
B. Start metoprolol and methimazole
C. Perform cardioversion before achieving euthyroid state
D. Administer radioactive iodine as first-line therapy
Answer: B. Start metoprolol and methimazole
Beta-blockers control heart rate in thyrotoxic atrial fibrillation, and methimazole
reduces thyroid hormone production. Amiodarone contains iodine and can worsen
hyperthyroidism. Cardioversion is less effective if the patient is not euthyroid. RAI is
not immediate and does not address the acute arrhythmia.
3. Which of the following best explains the mechanism of action of metformin
beyond its effect on hepatic gluconeogenesis?
A. Increases insulin secretion from pancreatic beta cells
B. Inhibits alpha-glucosidase in the small intestine
C. Activates AMPK in skeletal muscle, enhancing glucose uptake
D. Blocks sodium-glucose cotransporter-2 in the renal tubules
Answer: C. Activates AMPK in skeletal muscle, enhancing glucose uptake
Metformin activates AMPK, which increases insulin sensitivity and glucose uptake in
muscle. It does not stimulate insulin secretion (sulfonylureas do), does not inhibit
alpha-glucosidase (acarbose), and does not block SGLT2 (empagliflozin).
Page 2
,4. In a patient with type 2 diabetes and established atherosclerotic cardiovascular
disease (ASCVD), which of the following antihyperglycemic agents is recommended
as first-line add-on to metformin according to current ADA guidelines?
A. Insulin glargine
B. SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit
C. DPP-4 inhibitor
D. Thiazolidinedione
Answer: B. SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit
ADA guidelines recommend an SGLT2 inhibitor or GLP-1 RA with cardiovascular
benefit (e.g., empagliflozin, liraglutide) as first add-on for patients with ASCVD. Insulin
is not first-line. DPP-4 inhibitors have neutral CV effects. Thiazolidinediones may
increase heart failure risk.
5. A patient with type 1 diabetes presents with nausea, vomiting, and abdominal
pain. Capillary blood glucose is 450 mg/dL. Urine ketones are large. Which of the
following laboratory findings is most consistent with diabetic ketoacidosis (DKA)
rather than hyperosmolar hyperglycemic state (HHS)?
A. Serum osmolality 320 mOsm/kg
B. Serum bicarbonate 12 mEq/L
C. Serum sodium 150 mEq/L
D. Blood urea nitrogen 30 mg/dL
Answer: B. Serum bicarbonate 12 mEq/L
Low serum bicarbonate indicates metabolic acidosis, a hallmark of DKA. HHS
typically has higher osmolality (>320), higher sodium due to dehydration, and elevated
BUN, but bicarbonate is usually >18 mEq/L.
Page 3
, 6. Which of the following statements best describes the role of thyroid peroxidase
antibodies (TPOAb) in the diagnosis of autoimmune thyroid disease?
A. TPOAb is elevated in Graves' disease but not in Hashimoto's thyroiditis
B. TPOAb positivity confirms the diagnosis of Hashimoto's thyroiditis regardless of thyroid
function
C. TPOAb is a marker of autoimmune thyroid disease but not specific to a single condition
D. TPOAb levels correlate directly with thyroid hormone levels in hyperthyroidism
Answer: C. TPOAb is a marker of autoimmune thyroid disease but not specific to a
single condition
TPOAb is present in both Hashimoto's thyroiditis and Graves' disease, indicating
autoimmune etiology. It does not confirm Hashimoto's alone (B is false). It is not
exclusive to Graves' (A). TPOAb levels do not correlate with thyroid hormone levels
(D).
7. A patient with subclinical hypothyroidism (TSH 6.5 mIU/L, free T4 normal) is
planning pregnancy. Which of the following is the most appropriate management?
A. No treatment; monitor TSH every 6 months
B. Start levothyroxine to achieve TSH <2.5 mIU/L
C. Start methimazole to prevent fetal goiter
D. Perform thyroid ultrasound and fine-needle aspiration
Answer: B. Start levothyroxine to achieve TSH <2.5 mIU/L
In pregnancy planning, subclinical hypothyroidism should be treated to reduce risk of
adverse outcomes. Target TSH <2.5 mIU/L. Methimazole is for hyperthyroidism.
Ultrasound/aspiration is not indicated unless nodules are present.
8. Which of the following is a key advantage of using continuous glucose monitoring
(CGM) over self-monitoring of blood glucose (SMBG) in the management of type 1
diabetes?
A. CGM eliminates the need for insulin dose adjustments
B. CGM provides real-time glucose trends and alerts for hypoglycemia
C. CGM is less expensive than SMBG
D. CGM measures glycated hemoglobin directly
Answer: B. CGM provides real-time glucose trends and alerts for hypoglycemia
CGM offers trend data and alarms for hypo/hyperglycemia, improving glycemic
control and reducing hypoglycemia. It does not replace insulin adjustments (A), is more
expensive (C), and does not measure HbA1c (D).
Page 4
